A new vaccine for yellow fever that is safe for everyone.
A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine
This study is testing a new yellow fever vaccine called HydroVax-YFV to see if it's safe and effective for people who can't get the usual vaccine, like infants, pregnant women, and older adults.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Najit Technologies, INC. NIH-funded |
| Lab location | 1 site (Beaverton, UNITED STATES) |
| Project ID | NIH-10654651 on NIH RePORTER |
What this research studies
This research investigates a novel inactivated yellow fever vaccine, HydroVax-YFV, designed to be safe for vulnerable populations who cannot receive the current live attenuated vaccine. The study aims to evaluate the safety and efficacy of this new vaccine in a randomized clinical trial format. Participants will be monitored for any adverse effects and immune responses to ensure the vaccine's safety profile. The goal is to provide a viable vaccination option for individuals at risk, including infants, pregnant women, and the elderly.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who are unable to receive the live yellow fever vaccine due to age, pregnancy, breastfeeding, or egg allergies.
Not a fit: Patients who are healthy adults without contraindications to the current yellow fever vaccine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safe vaccination option against yellow fever for individuals who are currently at risk due to contraindications with the existing vaccine.
How similar studies have performed: While the current approach is novel, previous research has shown that inactivated vaccines can be effective alternatives to live attenuated vaccines in other contexts.
Where this research is happening
Beaverton, UNITED STATES
- Najit Technologies, INC. — Beaverton, United States (Active)
Researchers
- Principal investigator: Amanna, Ian James — Najit Technologies, INC.
- Study coordinator: Amanna, Ian James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.